Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Radiotherapeutics remain in the deal-making frame
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
Novartis turns to Beigene for a PD-1 blocker
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
